Advancements in Alzheimers disease | Dominantly Inherited Alzheimer Network (DIAN) | Washington University in St. Louis

New drug targets for Alzheimer’s identified from cerebrospinal fluid (Links to an external site)

November 14, 2024December 11, 2024

(Photo: Getty Images)

Study pegs certain cellular activities to driving Alzheimer’s disease. Researchers at Washington University School of Medicine in St. Louis have linked disease-related proteins and genes to identify specific cellular pathways responsible for Alzheimer’s genesis and progression.

The New Age of Alzheimer’s (Links to an external site)

April 18, 2024October 7, 2024

The soaring burden of dementia threatens global health. Science is paving new paths to solutions.

Podcast: Newly approved drug may slow progression of Alzheimer’s (Links to an external site)

August 4, 2023June 18, 2024

Lilly drug slows Alzheimer’s by 35%, bolstering treatment approach (Links to an external site)

May 8, 2023

Conquering Alzheimer’s: a look at the therapies of the future (Links to an external site)

April 7, 2023

Focused ultrasound technique leads to release of neurodegenerative disorders biomarkers (Links to an external site)

February 3, 2023February 3, 2023

FDA APPROVES LEQEMBI™ (LECANEMAB-IRMB) UNDER THE ACCELERATED APPROVAL PATHWAY FOR THE TREATMENT OF ALZHEIMER’S DISEASE (Links to an external site)

January 7, 2023

WashU, Eisai form drug discovery collaboration (Links to an external site)

December 16, 2022

[Ad hoc announcement pursuant to Art. 53 LR] Roche provides update on Phase III GRADUATE programme evaluating gantenerumab in early Alzheimer’s disease (Links to an external site)

November 15, 2022

LECANEMAB CONFIRMATORY PHASE 3 CLARITY AD STUDY MET PRIMARY ENDPOINT, SHOWING HIGHLY STATISTICALLY SIGNIFICANT REDUCTION OF CLINICAL DECLINE IN LARGE GLOBAL CLINICAL STUDY OF 1,795 PARTICIPANTS WITH EARLY ALZHEIMER’S DISEASE (Links to an external site)

September 28, 2022